[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100568241":3},{"organization":4,"armGroups":7,"interventions":39,"overallOfficials":16,"centralContacts":16,"locations":45,"responsibleParty":138,"collaborators":16,"id":140,"slug":141,"hasResults":142,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":142,"sex":148,"minAge":149,"maxAge":16,"enrollmentInfo":150,"targetDuration":16,"studyType":153,"phases":154,"briefSummary":157,"conditions":158,"keywords":163,"overallStatus":48,"whyStopped":16,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":176},{"fullName":5,"class":6},"Recursion Pharmaceuticals Inc.","INDUSTRY",[8,14,18,21,24,27,30,33,36],{"label":9,"type":10,"description":11,"interventionNames":12},"Phase 1a","EXPERIMENTAL","Dose Finding",[13],"Drug: REC-1245",{"label":15,"type":10,"description":16,"interventionNames":17},"Phase 1b Cohort A",null,[13],{"label":19,"type":10,"description":16,"interventionNames":20},"Phase 1b Cohort B",[13],{"label":22,"type":10,"description":16,"interventionNames":23},"Phase 1b Cohort C",[13],{"label":25,"type":10,"description":16,"interventionNames":26},"Phase 1b Cohort D",[13],{"label":28,"type":10,"description":16,"interventionNames":29},"Phase 2 Cohort 1 Dose #1",[13],{"label":31,"type":10,"description":16,"interventionNames":32},"Phase 2 Cohort 1 Dose #2",[13],{"label":34,"type":10,"description":16,"interventionNames":35},"Phase 2 Cohort 2 Dose #1",[13],{"label":37,"type":10,"description":16,"interventionNames":38},"Phase 2 Cohort 2 Dose #2",[13],[40],{"type":41,"name":42,"description":43,"armGroupLabels":44,"otherNames":16},"DRUG","REC-1245","Oral",[9,15,19,22,25,28,31,34,37],[46,66,81,92,107,124],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"City of Hope","RECRUITING","Duarte","California","91010","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-117.97729,34.13945,{"lat":58,"lon":57},[61],{"name":62,"role":63,"phone":64,"phoneExt":16,"email":65},"Mihae Song","CONTACT","877-467-3411","misong@coh.org",{"facility":67,"status":48,"city":68,"state":69,"zip":70,"country":52,"countryCode":53,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"Cleveland Clinic","Cleveland","Ohio","44195",{"type":55,"coordinates":72},[73,74],-81.69541,41.4995,{"lat":74,"lon":73},[77],{"name":78,"role":63,"phone":79,"phoneExt":16,"email":80},"Jessica Grenbenc","216-444-7923","canceranswer@ccf.org",{"facility":82,"status":83,"city":84,"state":85,"zip":86,"country":52,"countryCode":53,"cosmosGeoPoint":87,"geoPoint":91,"contacts":16},"SCRI Oncology Partners - PPDS","WITHDRAWN","Nashville","Tennessee","37203",{"type":55,"coordinates":88},[89,90],-86.78444,36.16589,{"lat":90,"lon":89},{"facility":93,"status":48,"city":94,"state":95,"zip":96,"country":52,"countryCode":53,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"START Mountain Region","West Valley City","Utah","84119",{"type":55,"coordinates":98},[99,100],-112.00105,40.69161,{"lat":100,"lon":99},[103],{"name":104,"role":63,"phone":105,"phoneExt":16,"email":106},"Marie Asay","801-907-4750","marie.asay@startresearch.com",{"facility":108,"status":48,"city":109,"state":110,"zip":111,"country":112,"countryCode":113,"cosmosGeoPoint":114,"geoPoint":118,"contacts":119},"Princess Margaret Cancer Centre","Toronto","Ontario","M5G 1X6","Canada","CA",{"type":55,"coordinates":115},[116,117],-79.39864,43.70643,{"lat":117,"lon":116},[120],{"name":121,"role":63,"phone":122,"phoneExt":16,"email":123},"Anh Nguyen","416-946-4501","anh.nguyen2@uhn.ca",{"facility":125,"status":48,"city":126,"state":16,"zip":127,"country":112,"countryCode":113,"cosmosGeoPoint":128,"geoPoint":132,"contacts":133},"McGill University Health Centre (MUHC) - The Montreal","Québec","H4A3J1",{"type":55,"coordinates":129},[130,131],-71.21454,46.81228,{"lat":131,"lon":130},[134],{"name":135,"role":63,"phone":136,"phoneExt":16,"email":137},"Phuong-nam Nguyen","5149341934","Phuong-nam.Nguyen@muhc.mcgill.ca",{"type":139,"investigatorFullName":16,"investigatorTitle":16,"investigatorAffiliation":16,"oldNameTitle":16,"oldOrganization":16},"SPONSOR","100568241","phase-1-a-study-of-rec-1245-in-participants-with-unresectable-locally-advanced-or-metastatic-cancer-100568241",false,"NCT06678659","A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer","A Phase 1 \u002F 2, Open-Label Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer","DAHLIA","Inclusion Criteria:\n\n* Have histologically-confirmed unresectable, locally advanced, or metastatic select solid tumors or select relapsed \u002F refractory lymphoma\n* Have experienced progressive disease, relapsed disease, or be intolerant to at least one established standard systemic anti-cancer treatment for a given tumor type, or have been considered ineligible for standard therapy.\n* Eastern cooperative oncology group (ECOG) performance status ≤1; for adolescent participants, Lansky Performance Status Scale or Karnofsky Performance Status Scale score of ≥70.\n* Measurable disease at baseline per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 \u002F Lugano criteria and documented by computed tomography (CT) and \u002F or magnetic resonance imaging (MRI)\n\nExclusion Criteria:\n\n* Received treatment with another RBM39 degrader\n* Clinically significant gastrointestinal (GI) or GI malabsorption","ALL","12 Years",{"count":151,"type":152},170,"ESTIMATED","INTERVENTIONAL",[155,156],"PHASE1","PHASE2","This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.",[159,160,161,162],"Unresectable","Locally Advanced","Metastatic Cancers","Relapsed\u002FRefractory Lymphomas",[164,165,166,161],"RBM39","Cancer","Refractory Lymphomas","2026-05-06",{"date":169,"type":170},"2026-05-08","ACTUAL",{"date":172,"type":170},"2024-11-21",{"date":174,"type":152},"2028-10-30",{"name":5,"class":6},6]